Streetbeat News

Stock Prices

DKNG

DraftKings (NASDAQ:DKNG) has received mostly bullish analyst ratings in the last quarter, with an average 12-month price target of $26.15, up 12.91% from the previous average of $23.16.

Portfolio Pulse from Benzinga Insights

May 22, 2023 | 12:14 pm

GHL

Mizuho announced it will acquire Greenhill & Co. (GHL) for $15 per share, causing GHL shares to trade higher.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:13 pm

MGNI

In the last quarter, Magnite (NASDAQ:MGNI) received 9 bullish and 2 somewhat bullish ratings from 11 analysts. The average 12-month price target for the stock is $15.27, up 13.11% from the previous average of $13.50.

Portfolio Pulse from Benzinga Insights

May 22, 2023 | 12:12 pm

IMMX

Immix Biopharma shares gained 44.5% in pre-market trading after disclosing positive clinical results for NXC-201 at The American Society of Gene and Cell Therapy. Other pre-market gainers include SeqLL, CNS Pharmaceuticals, Hepion Pharmaceuticals, and Netcapital. Losers in pre-market trading include Volcon, Daxor Corporation, SunCar Technology Group, Mallinckrodt, and IZEA Worldwide.

Portfolio Pulse from Lisa Levin

May 22, 2023 | 12:11 pm

CNTA

Centessa Pharmaceuticals has received Fast Track Designation from the FDA for its hemophilia B treatment, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:09 pm

FWBI

GMDA

HOOK

Gamida Cell Ltd. (NASDAQ:GMDA) has appointed Terry Coelho as CFO, effective immediately, replacing Shai Lankry who will leave the company on June 2. Coelho brings over 35 years of experience and currently serves as an independent director on the boards of First Wave BioPharma (NASDAQ:FWBI) and HOOKIPA Pharma (NASDAQ:HOOK).

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:08 pm

CMP

Compass Minerals (CMP) has entered into a lithium supply agreement with Ford, causing its shares to trade higher.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:08 pm

ORA

7 analysts have provided ratings for Ormat Technologies (NYSE:ORA) within the last quarter, with an average price target of $94.14, implying an upside from the current price of $83.47. The current average has decreased by 4.43% from the previous average price target of $98.50.

Portfolio Pulse from Benzinga Insights

May 22, 2023 | 12:05 pm

RAIN

Rain Oncology's Phase 3 MANTRA trial of Milademetan in dedifferentiated liposarcoma did not meet its primary endpoint of progression-free survival, compared to the standard of care, Trabectedin.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:04 pm

RRC

19 analysts have provided ratings for Range Resources (NYSE:RRC) in the last quarter, with an average price target of $31.26, implying an upside from the current price of $29.335. The average price target has increased by 4.51% over the past month.

Portfolio Pulse from Benzinga Insights

May 22, 2023 | 12:02 pm